270 related articles for article (PubMed ID: 22138582)
1. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.
Gerhardt J; Montani M; Wild P; Beer M; Huber F; Hermanns T; Müntener M; Kristiansen G
Am J Pathol; 2012 Feb; 180(2):848-61. PubMed ID: 22138582
[TBL] [Abstract][Full Text] [Related]
2. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
3. Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells.
Shiota M; Yokomizo A; Kashiwagi E; Takeuchi A; Fujimoto N; Uchiumi T; Naito S
Free Radic Biol Med; 2011 Jul; 51(1):78-87. PubMed ID: 21539911
[TBL] [Abstract][Full Text] [Related]
4. Forkhead-box A1 transcription factor is a novel adverse prognosis marker in human glioma.
Wang L; Qin H; Li L; Feng F; Ji P; Zhang J; Li G; Zhao Z; Gao G
J Clin Neurosci; 2013 May; 20(5):654-8. PubMed ID: 23510544
[TBL] [Abstract][Full Text] [Related]
5. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
6. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.
Imamura Y; Sakamoto S; Endo T; Utsumi T; Fuse M; Suyama T; Kawamura K; Imamoto T; Yano K; Uzawa K; Nihei N; Suzuki H; Mizokami A; Ueda T; Seki N; Tanzawa H; Ichikawa T
PLoS One; 2012; 7(8):e42456. PubMed ID: 22879989
[TBL] [Abstract][Full Text] [Related]
7. Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.
Shiota M; Song Y; Yokomizo A; Tada Y; Kuroiwa K; Eto M; Oda Y; Inokuchi J; Uchiumi T; Fujimoto N; Seki N; Naito S
Endocr Relat Cancer; 2010 Jun; 17(2):455-67. PubMed ID: 20308360
[TBL] [Abstract][Full Text] [Related]
8. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
Sahu B; Laakso M; Pihlajamaa P; Ovaska K; Sinielnikov I; Hautaniemi S; Jänne OA
Cancer Res; 2013 Mar; 73(5):1570-80. PubMed ID: 23269278
[TBL] [Abstract][Full Text] [Related]
9. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
10. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
11. Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer.
Kang HY; Huang HY; Hsieh CY; Li CF; Shyr CR; Tsai MY; Chang C; Chuang YC; Huang KE
J Bone Miner Res; 2009 Jul; 24(7):1180-93. PubMed ID: 19257827
[TBL] [Abstract][Full Text] [Related]
12. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates.
Beer M; Montani M; Gerhardt J; Wild PJ; Hany TF; Hermanns T; Müntener M; Kristiansen G
Prostate; 2012 Feb; 72(3):318-25. PubMed ID: 21739464
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mashima T; Okabe S; Seimiya H
Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
[TBL] [Abstract][Full Text] [Related]
14. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
[TBL] [Abstract][Full Text] [Related]
15. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
Cheng H; Snoek R; Ghaidi F; Cox ME; Rennie PS
Cancer Res; 2006 Nov; 66(21):10613-20. PubMed ID: 17079486
[TBL] [Abstract][Full Text] [Related]
16. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients.
Crnalic S; Hörnberg E; Wikström P; Lerner UH; Tieva A; Svensson O; Widmark A; Bergh A
Endocr Relat Cancer; 2010 Dec; 17(4):885-95. PubMed ID: 20688881
[TBL] [Abstract][Full Text] [Related]
17. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
18. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
19. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
[TBL] [Abstract][Full Text] [Related]
20. Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially.
Yu X; Gupta A; Wang Y; Suzuki K; Mirosevich J; Orgebin-Crist MC; Matusik RJ
Ann N Y Acad Sci; 2005 Dec; 1061():77-93. PubMed ID: 16467259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]